# Super Bowl Ads & GLP-1 Competition 2/9/26

An episode of [Squawk Pod](https://invisiblenetwork.ai/podcast/1480890290), 9 Feb 2026, 37 min.

Audio: https://dts.podtrac.com/redirect.mp3/cnbc.simplecastaudio.com/2abef7ca-625f-4c74-9157-968d7da67c81/episodes/478e4650-5ed7-4c4e-aa1a-c91820a5dbda/audio/128/default.mp3?aid=rss_feed&awCollectionId=2abef7ca-625f-4c74-9157-968d7da67c81&awEpisodeId=478e4650-5ed7-4c4e-aa1a-c91820a5dbda&feed=VHAcgaw_

National Economic Council Director Kevin Hassett discusses America’s economic trajectory, including the jobs market and productivity, inflation, and President Trump’s pick for new Fed chair, Kevin Warsh. Direct-to-consumer telehealth Hims & Hers made waves last month when it announced a cheaper, compounded obesity pill similar to Wegovy. Now, after the FDA warned against compounded GLP-1s, Hims & Hers is backing off. Former FDA Commissioner Dr. Scott Gottlieb discusses competition in obesity drugs, Novo Nordisk’s lawsuit against Hims & Hers, and the importance of vaccines. Plus, the pharma and AI ads at Super Bowl LX, Japanese Prime Minister Sanae Takaichi secured a supermajority in a snap election, and CNBC’s Emily Wilkins reports on the legislative efforts to address the U.S. housing affordability crisis. Emily Wilkins - 10:09 Kevin Hassett - 19:21 Dr. Scott Gottlieb - 30:10 In this episode: Emily Wilkins, @emrwilkins Becky Quick, @BeckyQuick Joe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkin Cameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them.
